ReviewFrontiers in medical technology2026
Translational advances in diabetic nephropathy management: integrating nanoformulation-based drug delivery systems.
Review in Frontiers in medical technology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The incidence of diabetes mellitus (DM) is increasing worldwide, especially for its major renal complications, diabetic nephropathy (DN) and chronic kidney disease (CKD). These are caused by chronic hyperglycemia, oxidative stress, hemodynamics, inflammation, and profibrotic signaling, which result in progressive renal structural damage and functional decline. All these mechanisms contribute to podocyte injury, thickening of the glomerular basement membrane, interstitial fibrosis, and progressive loss of renal function. While traditional diagnostic markers like albuminuria or estimated glomerular filtration rate (eGFR) aid in tracking disease with imaging, and emerging markers like neutrophil gelatinase-associated lipocalin (NGAL), kidney injury molecule-1 (KIM-1), and cystatin C can help, none can detect early, subclinical kidney damage. A comprehensive literature review was conducted in PubMed, Google Scholar, Scopus, Web of Science, and ScienceDirect using keywords related to DN pathophysiology, diagnosis, nanomedicine, renal targeting, and nanoformulations, with publications between 2015 and 2026. Intensive glycemic and blood pressure control, inhibition of the renin-angiotensin-aldosterone system, and lipid-lowering therapy are currently used as therapeutic interventions. Poor bioavailability, off-target toxicity, complex dosing regimens, and variable renal drug handling are often responsible for their limited effectiveness. One approach to circumventing these limitations is with nanotechnology-based drug delivery systems. In preclinical studies, the antioxidant, anti-inflammatory, and antifibrotic effects have consistently been reported to be superior, with reduced systemic toxicity, while clinical translation remains in its early stages. This review discusses current knowledge on DN and critically evaluates the pros, cons, and future of nanotechnology-based approaches for delivering targeted nanomedicines to the kidney.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.